FDAnews Drug Daily Bulletin

Study Shows Frequent Bias in Published Breast Cancer Trials

Jan. 16, 2013
A A
An analysis of 164 phase III breast cancer trials shows bias in reporting the primary endpoint and toxicity results. Thirty-three percent of the trials published between 1995 and 2011 exhibited biased reporting of the prespecified primary endpoint. Sixty-seven percent showed bias in reporting toxicity rates.
Cancer Network